Enterosys welcomes its new CEO

CEO Jean-Christophe Malrieu

Enterosys has the unique combination of the scientific expertise, R&D skills and state-of-the-art technologies to become a leading preclinical CRO in its market.

With its technological lead in the investigation of the digestive sphere, Enterosys’ objective is to become the reference player in the field of the gut, the gut-brain axis and the gut-organ.

With such a line of investigation, Enterosys aims to become a key partner in research on neurodegenerative, metabolic and intestinal diseases.”

Jean-Christophe Malrieu is an entrepreneur with a Master’s degree in Business Management from the University of Paris Dauphine and a Bachelor’s degree in Economics. He had a long international experience in multinational companies such as Unilever (18 years) and Shiseido (4 years) before joining SME companies as CEO. He has extensive experience in innovation and development, marketing and sales, finance, export, food and beauty and, for 12 years, in healthcare. In 2010, he became president and CEO of Phythea, a French nutraceutical leader specializing in joint and women’s health. In early 2017, he co-founded A-Mansia Biotech SA in Belgium, a spin-off from Wageningen University and UC Leuven aiming to fight obesity and T2D with Akkermansia muciniphila, a key species of human gut microbiota discovered in 2006 by the company’s founders. In 2018, he raised €25 million to fund the development of A-Mansia, including €18 million in a Series A round. In December 2021, he decided to join ENTEROSYS as CEO.




Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in hybrid format. Enterosys will be present with a validated, complete and innovative offer of in vitro and in vivo preclinical...

Enterosys welcomes its new business developer

Pauline Caseilles have joined the Enterosys team this month as Scientific Business Developer. Its aim is to publicize Enterosys' service offerings. Pauline obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks. Preterm infants are highly susceptible to oxidative stress due...

Targeting our second brain using prebiotics

The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia remains a major target....

Commercial H/F – Biotechnologie

What we will accomplish together Pursue your career with a pure player in preclinical testing and accompany us in our growth! We need your scientific knowledge and your commercial appetite to build the commercial division! We are waiting for you at a key moment of our...